S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:AUTL

Autolus Therapeutics Stock Forecast, Price & News

$8.77
+0.37 (+4.40 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.35
Now: $8.77
$8.77
50-Day Range
$8.13
MA: $9.07
$11.95
52-Week Range
$3.00
Now: $8.77
$17.19
Volume127,566 shs
Average Volume321,433 shs
Market Capitalization$458.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics logo

MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

812th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

110th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
CUSIPN/A
CIKN/A
Phone44-20-3829-6230
Employees290

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 million
Book Value$5.67 per share

Profitability

Net Income$-123,850,000.00
Net Margins-8,652.90%

Miscellaneous

Market Cap$458.23 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable
$8.77
+0.37 (+4.40 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

How has Autolus Therapeutics' stock price been impacted by Coronavirus?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have increased by 29.5% and is now trading at $8.77.
View which stocks have been most impacted by COVID-19
.

Is Autolus Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Autolus Therapeutics?

Wall Street analysts have given Autolus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Autolus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Autolus Therapeutics' CEO?

1,448 employees have rated Autolus Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Autolus Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Autolus Therapeutics
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.01. The company earned $0.68 million during the quarter, compared to analysts' expectations of $0.31 million. Autolus Therapeutics had a negative net margin of 8,652.90% and a negative return on equity of 54.01%.
View Autolus Therapeutics' earnings history
.

What price target have analysts set for AUTL?

8 equities research analysts have issued 12-month target prices for Autolus Therapeutics' stock. Their forecasts range from $13.00 to $38.00. On average, they anticipate Autolus Therapeutics' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 173.7% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 57)
  • Dr. Martin Pulé, Founder, Sr. VP, Chief Scientific Officer & Director (Age 49)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 59)
  • Mr. Christopher Vann, Sr. VP & COO (Age 56)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 56)
  • Dr. Muhammad Al-Hajj Ph.D., Sr. VP of Translational Sciences (Age 50)
  • Dr. Adam Hacker Ph.D., Sr. VP of Regulatory Affairs & Quality (Age 51)
  • Mr. David Brochu, Sr. VP of Product Delivery (Age 64)
  • Dr. Lucinda Crabtree Ph.D., VP of IR & Corp. Communications
  • Mr. Vishal Mehta, VP & Head of Clinical Operations

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Pendal Group Limited (0.10%).

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was acquired by a variety of institutional investors in the last quarter, including Pendal Group Limited.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $8.77.

How big of a company is Autolus Therapeutics?

Autolus Therapeutics has a market capitalization of $458.23 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis. Autolus Therapeutics employs 290 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.